Authors: Neurology Central
Neurology Central conducted a poll to find out your opinions on the recent results from the aducanumab drug trial for Alzheimer’s disease. We asked whether the aducanumab trial could lead to a successful treatment for the disease, and you were almost evenly split, with 55% of respondents voting ‘Yes’ and 45% voting ‘No’. To see the rest of our findings, take a look at our infographic below.
For further information on the aducanumab trial take a look at our news coverage, and for a full review of the research paper read this article from our Journal Watch columnist, David Howett.